Medical Devices & Tech


60 rue de Wattignies, Bat B, 3rd Floor
Paris, 75012 France
Click for website

Research Sector Medical Devices & Tech

Summary Description Non-invasive nanoparticle-based cancer therapy

Management Laurent Levy, Ph.D., Chairman and Chief Executive Officer; Kader Boussaha, M.B.A., Vice President and Chief Financial Officer; Elsa Borghi, M.D., Medical Drector

Click here for Financial Data
Keywords: Nanobiotix, cancer, nanotechnology, biotechnology, imaging, ultrasound, MRI, xray, nanoparticles, nanomedicine, SonoDrug, molecular biology, lung cancer, prostate cancer, breast cancer, colon cancer, pancreatic cancer, radiation therapy, radiotherapy


Updated: Sept. 11, 2017


Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray a technology platform that is expected to be turned "on" and ......view more

Products / Services

NanoXray is designed to resolve cancer therapy's biggest limitation. Use of NanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent del......view more

Technology / Differentiation

NanoXray consists of non-drug nanoparticles, designed to be introduced by injection, which then attach themselves only to specifically targeted cancer cells. NanoXray nanoparticles are comprised of ...view more

Market / Customers

One in four deaths in the U.S. is from cancer, making it the second-leading cause of death after heart attack. NanoXray offers a dramatic innovation in cancer therapy, based on a technology that is de......view more

Competitors / Substitutes / Alternatives

N/A...view more


The nanoparticles that comprise the NanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. NBTX3, the first product to be developed from the nanoXra...view more

Revenue / Funding

To date (05/09): $16 million: Amorage Rhne-Alpes, Cap Decisif, Matignon Technologies, OTC Asset Management...view more


Nanobiotix plans to commence clinical trials in the second half of 2009. The company announced the results of its preclinical trial in May 2009. The preclinical study, performed at Institut Gustave Ro...view more

Analyst Coverage

Fatal error: Uncaught Error: Call to undefined function echostr_replace() in /home/onemedpl/public_html/database/comp_profile_include.php:787 Stack trace: #0 /home/onemedpl/public_html/database/comp_profile.php(87): include() #1 {main} thrown in /home/onemedpl/public_html/database/comp_profile_include.php on line 787